



Amedisys Fourth Quarter and Full Year 2018 Earnings Call Supplemental Slides

February 28th, 2019

Forward-looking statements

This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events.

Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website <http://www.amedisys.com> or by contacting the Amedisys Investor Relations department at (225) 292-2031.

We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law.


www.amedisys.com

NASDAQ: AMED

We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business and clinical operations and control processes, and SEC filings.

A Look Back

FY 2018 Accomplishments (as compared to FY 2017 unless otherwise noted)



Our Key Areas of Focus

Strategic areas of focus for Q4 2018 and beyond

1



Organic Growth

- **Home Health***: Total same store admission +6%. Total same store volume +6%. Total same store Medicare admits +3%
- **Hospice**: Admissions +12%, ADC +9%
- **Personal Care**: Double digit growth in billable hours / quarter +14% (including acquisitions)

2



Recruiting / Retention

- Targeting industry leading employee retention amongst all employee categories – Full time voluntary turnover currently at 16.8%
- Focus on reduction of clinical turnover with heavy focus on RN's
- Continued improvement on engagement - overall satisfaction score of 75 (currently above industry average)

3



Clinical Initiatives

- Quality: Amedisys April 2019 STARS score of 4.28 reflects CMS change in measurement (added Improvement in Mgmt. of Oral Meds while removing Drug Education)
- 53 Amedisys care centers rated at 5-Stars in the April'19 Preview
- Hospice quality – outperforming industry average in all hospice item set (HIS) categories
- Continued focus on 30-Day and 60-Day ACH rate reduction

4



Capacity and Productivity

- Productivity driving continued CPV control (visiting clinician CPV up only \$0.39 year over year, in spite of \$1.15 cpv impact from annual raises)
- Focusing on optimizing RN / LPN & PT / PTA staffing ratios

5



M&A

- Closed Compassionate Care Hospice acquisition 2/1/19
 - 10.7x net purchase price multiple
 - 7.8x fully synergized
- Signed definitive agreement to acquire RoseRock Healthcare on 2/14/19
 - 200 ADC Hospice in Tulsa, OK
 - Expected closing: 4/1/19
- Tuck-in pipeline remains full
- Targeting increased de novo activity in 2019 (7-9 planned)

6



Regulatory

- 2019 Home Health industry impact per Proposed Rule +2.2%; AMED home health specific impact +1.2%
- AMED hospice specific impact +1.6% (effective 10/1/18)
- Working with CMS and Congress to address “behavioral assumptions” language in PDGM
- Three bills introduced aimed at mitigating “behavioral assumptions”

*Note: Home Health same store volume is defined as admissions plus recertifications

Highlights and Summary Financial Results (Adjusted): 4Q 2018⁽¹⁾



Home Health total same store volume +6%, total same store admissions +6%. Hospice same store admissions +12%. Personal Care +14% billable hours

4Q'18

Amedisys Consolidated

- Revenue Growth: +9%
- EBITDA: \$44M (+18%)
- EBITDA Margin: 10% (+80 bps)
- EPS: \$0.91 (+63%)

4Q'18

Balance Sheet & Cash Flow

- Net debt: \$(9.3)M
- Net Leverage ratio: -0.1x
- CFFO: \$64.0M (FY \$223.5M)
- Free cash flow ⁽⁴⁾: \$62.8M
- DSO: 38.0 (vs. Q4'17 of 44.0 and Q3'18 of 40.6)

4Q'18

Home Health

Same Store Volume ⁽²⁾:

- Total: +6%
- Episodic ⁽³⁾: +5%

Same Store Admissions:

- Total: +6%
- Episodic ⁽³⁾: +5%

Other Statistics:

- Revenue per Episode: \$2,891 (+\$33)
- Total Cost per Visit: \$92.36 (flat)
- Medicare Recert Rate: 37.8% (40) bps

4Q'18

Hospice

Same Store Volume:

- Admissions: +12%
- ADC: +9%

Other Statistics:

- Revenue per Day: \$151.46 (+1.9%)
- Cost per day: +2.9%

4Q'18

Personal Care

Growth Metrics ⁽⁵⁾:

- Billable hours/quarter: +14%
- Clients served: +3%

4Q'18

Adjusted Financial Results⁽¹⁾


\$ in Millions, except EPS	4Q17	4Q18	FY 2017	FY 2018
Home Health	281.9	304.0	1,090.4	1,176.2
Hospice	97.9	108.8	367.8	410.9
Personal Care	18.1	21.6	59.6	77.2
Total Revenue	\$ 398.0	\$ 434.4	\$ 1,517.8	\$ 1,664.3
Gross Margin %	39.9%	39.6%	40.5%	40.3%
Adjusted EBITDA	37.1	43.9	142.2	180.6
Adjusted EPS	9.3%	10.1%	9.4%	10.8%
Adjusted EPS	\$0.56	\$0.91	\$2.21	\$3.63
Free cash flow ⁽⁴⁾	\$29.7	\$62.8	\$95.1	\$214.3

- The financial results for the three-month periods and years ended December 31, 2017 and December 31, 2018 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
- Same Store volume – Includes admissions and recertifications.
- Episodic admissions and volume – Includes Medicare and non-Medicare payors that bill on a 60-day episode of care basis.
- Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.
- Includes acquisitions.



OUR REVENUE SOURCES: 4Q18


Amedisys Consolidated Revenue



■ Home Health ■ Hospice ■ Personal Care




Home Health Revenue



■ Medicare FFS ■ Private Episodic ■ Per Visit



Hospice Revenue



■ Medicare FFS ■ Private

- **Home Health:** 323 care centers; 34 states & DC
- **Hospice:** 84 care centers; 22 states
- **Personal Care:** 12 care centers; 3 states
- **Total AMED:** 419 care centers; 34 states and D.C.

Post acquisition of Compassionate Care Hospice

- **Hospice:** 137 care centers; 33 states
- **Total AMED:** 472 care centers; 38 states and D.C.

- **Medicare FFS:** Paid episodically over a 60 day episode
- **Private Episodic:** MA and Commercial plans who pay us over a 60 day episode. Generally at rates ~90% – 100% of Medicare
- **Per Visit:** Managed care, Medicaid and private payors reimbursing us per visit provided

Hospice Per Day Reimbursement:

- **Routine Care:** Patient at home with symptoms controlled – **97% of the Hospice care AMED provides**
- **Continuous Care:** Patient at home with uncontrolled symptoms
- **Inpatient Care:** Patient in facility with uncontrolled symptoms
- **Respite Care:** Patient at facility with symptoms controlled



Home Health and Hospice Segment (Adjusted) – 4Q 2018⁽¹⁾

Home health total volume growth strong (+6%); Hospice continues strong ADC growth (+9%)

HOME HEALTH		Year Ended		
\$ in Millions	4Q17	4Q18	2017	2018
Medicare	205.0	211.5	799.8	832.5
Non-Medicare	76.9	92.5	290.6	343.7
Home Health Revenue	\$281.9	\$304.0	\$1,090.4	\$1,176.2
Gross Margin %	38.0%	37.7%	38.5%	38.6%
Segment EBITDA ⁽²⁾	\$37.2	\$43.4	\$143.5	\$177.8
	13.2%	14.3%	13.2%	15.1%

Operating Statistics				
Same Store Growth ⁽³⁾				
Total Volume	7%	6%	4%	7%
Total Admissions	4%	6%	2%	5%
Episodic Volume	6%	5%	4%	5%
Episodic Admissions	3%	5%	2%	4%
Revenue per Episode	\$ 2,858	\$ 2,891	\$ 2,823	\$ 2,854
Recert Rate	38.2%	37.8%	36.8%	38.1%
Total Cost per visit	\$92.37	\$92.36	\$90.48	\$89.89

HOSPICE		Year Ended		
\$ in Millions	4Q17	4Q18	2017	2018
Medicare	92.7	103.5	350.7	390.2
Non-Medicare	5.2	5.3	17.1	20.7
Hospice Revenue	\$97.9	\$108.8	\$367.8	\$410.9
Gross Margin %	48.3%	47.8%	49.0%	48.4%
Segment EBITDA ⁽²⁾	\$26.8	\$29.1	\$103.8	\$114.3
	27.4%	26.8%	28.2%	27.8%

Operating Statistics				
Admit growth - same store	8%	12%	11%	8%
ADC growth - same store	12%	9%	15%	11%
Admits	6,371	7,152	25,381	27,596
ADC	7,162	7,809	6,820	7,588
Avg. discharge length of stay	96	103	93	100
Revenue per day (net)	\$148.62	\$151.46	\$147.75	\$148.36
Cost per day	\$76.81	\$79.02	\$75.31	\$76.53



Home Health Highlights

- Medicare FFS growth +3.2%
- Revenue per Episode up +\$33
- Recert rate down 40 bps; +130 bps FY
- CPV flat in Q4'18
- EBITDA as a % percentage of revenue: +110bps Q4; +190 bps FY'18



Hospice Highlights

- Same store average daily census (ADC) up 9% in 4Q
- Net revenue per day +1.9% in 4Q
- Three providers over cap as of Q4'18: ~\$0.4M liability for 2019 cap year
- Total cap expense for 2018: \$1.1M

1. The financial results for the three-month periods and years ended December 31, 2017 and December 31, 2018 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Segment EBITDA does not include any corporate G&A expenses.
3. Same store admissions and volume exclude 7 closed and consolidated care centers in FL during 2017.




General & Administrative Expenses – Adjusted ^(1,2)

Impact of G&A cost control materializing as operational efficiencies are realized; Adding investments to Hospice segment

\$ in Millions	4Q17	1Q18	2Q18	3Q18	4Q18
Home Health Segment - Total	70.0	68.1	68.3	68.8	71.2
% of HH Revenue	24.8%	24.0%	23.3%	23.3%	23.4%
Hospice Segment - Total	20.5	19.9	20.5	21.4	22.9
% of HSP Revenue	20.9%	20.5%	20.2%	20.7%	21.1%
Personal Care Segment - Total	3.1	3.2	3.2	3.0	3.2
% of PC Revenue	17.3%	17.9%	17.2%	15.8%	14.9%
Total Corporate Expenses	29.0	29.2	30.1	30.2	31.8
% of Total Revenue	7.3%	7.3%	7.3%	7.2%	7.3%
Total	122.6	120.4	122.1	123.4	129.1
% of Total Revenue	30.8%	30.2%	29.5%	29.6%	29.7%

Corp G&A	4Q17	1Q18	2Q18	3Q18	4Q18
Salary and Benefits	15.6	14.9	16.0	16.7	18.2
Other	10.2	11.6	11.8	10.2	10.0
Corp. G&A Subtotal	25.8	26.5	27.8	26.9	28.2
Non-cash comp	3.2	2.7	2.3	3.3	3.6
Adjusted Corporate G&A	29.0	29.2	30.1	30.2	31.8

Total G&A as a Percent of Revenue



Notes:

- **Year over year total G&A as a percentage of revenue decreased 110 basis points**
 - Home Health segment G&A: 140 bps decrease as % of revenue
 - Hospice segment G&A: 20 bps increase as % of revenue
 - Personal Care segment G&A: 240 bps decrease as % of revenue
 - Corporate G&A: Percent of total revenue flat versus prior year
- **Total G&A sequential increase driven by planned wage increases and anticipated health insurance increases**



1. The financial results for the three-month periods ended December 31, 2017, March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.

2. Adjusted G&A expenses do not include depreciation and amortization.

Industry Leading Quality Scores





Quality of Patient Care (QPC)

Metric	OCT 18 Release	JAN 19 Release	APR 19 PREVIEW
Quality of Patient Care	4.43	4.40	4.28
Entities at 4+ Stars	94%	94%	86%

Patient Satisfaction (PS)



Metric	JUL 18 Release	OCT 18 Release	JAN 19 Release
Patient Satisfaction Star	3.96	3.66	3.75
Performance Over Industry	+7%	+5%	+6%



Note: Top Competitor Avg weighted by CCN count and include LHC, Kindred, AFAM, HLS and BKD

- Amedisys maintains a 4-Star average in the Apr 2019 HHC preview with **86% of our providers at 4+ Stars and 53% at 4.5+ Stars**
- **29 Amedisys providers (representing 53 care centers) rated at 5-Stars in the Apr HHC 2019 preview**
- In April 19 Preview for QPC, new measure introduced: **Improvement in Management of Oral Meds**
- AMED received ~\$1M in bonus payments related to Value Based Purchasing (VBP) YTD through 4Q'18

Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class






Operational Excellence: Home Health Cost Per Visit (CPV)

Total CPV impacted by planned wage increases

Components	4Q'17	3Q'18	4Q'18	YoY Variance	Detail	Mitigation Plan
Salaries	\$61.80	\$61.93	\$62.79	\$0.99	YoY increase due to planned wage increases offset by volume growth and increased productivity	Staffing mix optimization, productivity and scheduling improvement initiatives in place helped us overcome planned salary increases
Contractors	\$2.93	\$3.35	\$3.38	\$0.45	YoY increased demand due to increasing volumes	Focused efforts on filling positions with full-time clinicians
Benefits	\$12.35	\$11.14	\$11.60	(\$0.75)	YoY reduction driven by decrease in workers comp expense. Sequential increase driven by seasonality of health insurance claims	Focus on cost containment and spend optimization with specific focus on high cost claims
Transportation & Supplies	\$6.80	\$6.36	\$6.50	(\$0.30)	YoY decrease primarily due to supplies costs	More effective medical supply contracting cost initiatives are underway
*Visiting Clinician CPV	\$83.88	\$82.78	\$84.27	\$0.39		
Clinical Managers	\$8.49	\$8.18	\$8.09	(\$0.40)	Fixed cost associated with non-visiting clinicians	Unit cost reduced as volume increases
Total CPV	\$92.37	\$90.96	\$92.36	(\$0.01)		

*Note: Direct comparison with industry competitors CPV calculation


Cost Per Visit (CPV)





Driving Top Line Growth

All three lines of business continue to grow. Hospice delivers another quarter of ADC growth and Home Health total same store volume continues to trend in the mid-single digits



*Total Home Health Same Store Volumes exclude 7 closed and consolidated care centers in Florida in 2017

*Includes impact of Intercity (10/2/17), East Tennessee (5/1/18) and Bring Care Home (10/1/18) acquisitions



AMEDISYS TO ACQUIRE COMPASSIONATE CARE HOSPICE

Deal Summary



Overview

- Amedisys closes on its acquisition of Compassionate Care Hospice
 - 100% stock purchase
- Compassionate Care Hospice:
 - Founded in 1993
 - 100% founder owned
 - **Average Daily Census: 3,300**
 - Revenue: \$188M
 - **Adj. EBITDA: \$27M (TTM May'18)**
 - Care Centers: 53
 - FTE's: ~2,300
 - States: 24
- Proforma for acquisitions, AMED becomes the **3rd largest hospice provider in America**
- Adds 11 new states to AMED hospice organization

Metrics

- **\$340M gross price (12.6x)**
- **\$290M net price (10.7x)**
 - Net of \$50M dollar for dollar payment related to tax asset and working capital
- **Synergized Multiple: 7.8x**
 - ~\$10M in synergies
- Overlap: Minimal overlap ~10% of ADC
- Balance sheet remains very flexible for continued inorganic growth opportunities:
 - **Initial leverage ratio: ~1.6x**
 - Proforma company will have significant cash generation

Integration

- Conversion to HCHB to begin March 1 and projected to take ~180 days
 - **Expect to see integration and HCHB implementation disruption during 1Q'19 and 2Q'19 impacting census and costs**
- **AMED will invest in the business during 2019** to grow low ADC care centers and expand margin in large care centers
 - Adding sales resources to accelerate growth in 2H'19 and 2020
 - Retention packages for key employees
 - Care center staffing model and regional infrastructure
- Expect significant margin improvement throughout 2020
 - **2021 expect margin profile similar to AMED hospice**

Debt and Liquidity Metrics

Our debt levels remain very low at (0.1)x net leverage. Pro forma for Compassionate Care Hospice, our leverage still remains low at ~1.6x net leverage

Outstanding Debt		Pro Forma for Acquisition Adjustments as of 12/31/18	
	As of: 12/31/18	Adjustments	Pro Forma
Outstanding Revolver / Other Notes Payable	10.9	340.0	350.9
Total Debt Outstanding	10.9	340.0	350.9
Less: Deferred Debt Issuance Costs	(3.5)	-	(3.5)
Total Debt - Balance Sheet	7.4	340.0	347.4
Total Debt Outstanding	10.9	340.0	350.9
Less: Cash	(20.2)	-	(20.2)
Net Debt ⁽¹⁾	(9.3)	340.0	330.7
Leverage Ratio (net) ⁽²⁾	(0.1)		1.6
Credit Facility		Pro Forma for Acquisition Adjustments as of 12/31/18	
	As of: 12/31/18	Adjustments	Pro Forma
Term Loan	-	175.0	175.0
Revolver Size	550.0	-	550.0
Borrowing Capacity	550.0	175.0	725.0
Outstanding Revolver	(7.5)	(165.0)	(172.5)
Letters of Credit	(34.1)	-	(34.1)
Available Revolver	508.4	(165.0)	343.4
Plus: Cash	20.2	-	20.2
Total Liquidity ⁽³⁾	528.6	(165.0)	363.6



1. Net debt defined as total debt outstanding (\$10.9M) less cash balance (\$20.2M).
2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA (\$181M); Pro Forma for CCH (\$208M).
3. Liquidity defined as the sum of cash balance and available revolving line of credit.

Cash Flow Statement Highlights ⁽¹⁾

\$62.8M in free cash flow for the quarter; \$223.5M in cash flow from operations for the year up ~\$118M from 2017

\$ in Millions	1Q18	2Q18	3Q18	4Q18	FY 2018	FY 2017
GAAP Net Income	27.3	33.5	31.5	27.7	120.1	30.7
Changes in working capital	(2.0)	2.1	20.1	17.4	37.6	(35.7)
Depreciation and amortization	3.6	3.1	3.2	3.4	13.3	17.1
Non-cash compensation, includes 401(k) match expense	6.6	6.1	6.9	7.3	26.9	25.0
Deferred income taxes	2.9	6.2	5.8	5.4	20.3	52.2
Other	1.9	(0.3)	1.0	2.8	5.3	16.4
Cash flow from operations	40.3	50.7	68.5	64.0	223.5	105.7
Capital expenditures - routine	(1.3)	(0.1)	(3.2)	(0.8)	(5.4)	(5.3)
Required debt repayments	(2.8)	-	(0.6)	(0.4)	(3.8)	(5.3)
Free cash flow	36.2	50.6	64.7	62.8	214.3	95.1
Capital Deployment						
Acquisitions	(2.3)	(1.8)	-	(5.2)	(9.3)	(33.7)
Equity Investments	-	-	(3.5)	(3.7)	(7.1)	-
Share Repurchases	-	(181.4)	-	-	(181.4)	-
Total	(2.3)	(183.2)	(3.5)	(8.9)	(197.8)	(33.7)



1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.

Income Statement Adjustments ⁽¹⁾

\$000s	Income Statement Line Item	1Q18	2Q18	3Q18	4Q18	FY 18
Revenue						
Florida self-audit (pre-acquisition)	Net Service Revenue		1,687			1,687
G&A						
Acquisition costs	G&A, Other	435	440	857	1,025	2,757
Legal fees - non-routine	G&A, Other	562	543	304	56	1,465
Indemnity receivable adjustment	G&A, Other				2,143	2,143
Other Items						
Legal settlements	Other, Miscellaneous, net			(1,437)		(1,437)
Miscellaneous, other (income) expense, net	Other, Miscellaneous, net	(809)	(1,635)	(333)	(100)	(2,876)
Total		188	1,035	(609)	3,124	3,739
EPS Impact		\$ -	\$ 0.02	\$ (0.01)	\$ 0.07	\$ 0.08



1. The financial results for the three-month periods ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018, and year ended December 31, 2018 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.

Amedisys 2019 Preliminary Guidance

Targeting ~16% - 19% growth in revenue, ~13% - 16% growth in EBITDA and ~10% - 13% growth in EPS

	2018 Actual Performance	2019 Guidance
Revenue	\$1.66B	\$1.94B - \$1.98B
Adjusted EBITDA	\$180.6M	\$205M - \$210M
Adjusted Earnings per Share	\$3.63	\$3.98 - \$4.09

Amedisys 2019 Guidance Considerations

Project solid revenue and earnings growth while investing in our people and the business to prepare for PDGM and beyond. Executing inorganic growth strategy and ramping up de novos

Amedisys Consolidated

- **Tax rate ~26%**
- **Cash tax rate ~17%**
- Diluted share count ~**33.1 million shares**
- Capital Expenditures ~**\$8-\$10 million**
- Salary increase ~**2% - 3%**
- Benefits increase ~**12%** (8% growth / headcount, 4% pricing / claims costs)
- Overall ~**\$6 million** investment in business development resources
- **Excludes future acquisitions and related integration costs**



Home Health

- **Total same store admission growth ~5%**
- Focus on business development staffing strategy ~**\$3 million (Y/Y increase)**
- Continue focus on Quality of Care (Stars and Acute Care Hospitalization rates)
- Continued positive progress on underperforming care centers



Hospice

- **Total same store admission growth ~7%**
- Addition of business development resources to maintain organic growth ~**\$3 million**
- **Includes contribution of CCH acquisition of ~\$12M-\$14M**
 - Decline in exit rate TTM (\$25M vs. \$27M)
 - ADC Disruption of ~100 (~3%)



Personal Care


- **Total billable hours growth ~13%**
- Employer Medical Assistance Contribution (EMAC) ~**\$1 million**

2019 Investments

- **Total Investments in business of ~\$7M**
 - IT Security – Investments in IT security enhancements for web, ID, data and e-mail protection etc.
 - Pay Practice Redesign – Incentivizing our clinical staff to work at the top of their license (right people, doing the right visits)
 - Staffing Model Redesign – Optimizing our care centers and field infrastructure to maximize operational efficiency
 - PDGM Resources – Investments in teams, projects, processes needed to thrive in PDGM
 - De Novos – 7 to 9 de novos planned for 2019

Compassionate Care Hospice (CCH) EBITDA Improvement

HCHB disruption and investments in the business will impact EBITDA in 2019. EBITDA margin in 2020 and beyond will reflect legacy Amedisys hospice margin and growth trajectory



Category	Description
ADC Disruption	Negative impact on ADC as HCHB is installed. Expect ADC to recover in 3Q'19
Investment	Investments needed in regional infrastructure and BD staff to grow low ADC care centers and improve margin in large ADC care centers. Current CCH EBITDA margin approximately half of legacy AMED and growth rate ~20% of AMED ADC growth
Synergies and Other Efficiencies	Cost savings, duplicative contract optimization and sunset of current IT system; cannot begin to pull costs out until HCHB is installed. Realize 100% of run rate synergies of ~\$10M in 2H'2020

Reimbursement Outlook

2019 Reimbursement Impact for Home Health and Hospice



Home Health

	2019
Market Basket Update	3.0%
Productivity Adjustment	(0.8)
Estimated Industry Impact	+2.2%
Estimated AMED-Specific Impact	+1.2%

Note: +2.2% industry impact compared to +1.2% AMED specific impact ~(\$8M)




Hospice

	2019*
Market Basket Update	2.9%
Productivity / Other Adjustment	(1.1)
Estimated Industry Impact	+1.8%
Estimated AMED-Specific Impact	+1.6%

*Hospice rate increase effective October 1, 2018

EBITDA Seasonality: As Reported


Adjusted EBITDA



Drivers of Seasonality	Q1	Q2	Q3	Q4
	<ul style="list-style-type: none"> • Weather disruption • Lower RPE (LUPA) • Payroll tax reset • Short Month (Feb.) • Lower Hospice ADC & Higher Salary Cost per Day 	<ul style="list-style-type: none"> • Highest Completed Episodes • Stronger revenue per episode (RPE) 	<ul style="list-style-type: none"> • Incremental holiday vs. 1H • High PTO • Lower Volumes • Health Insurance Increases • Raises 	<ul style="list-style-type: none"> • Incremental holiday vs. 1H • Health Insurance Increases • Better Volumes • Raises

EBITDA Seasonality: Excluding Health Insurance and Workers Compensation

Adjusted EBITDA



Drivers of Seasonality	Q1	Q2	Q3	Q4
	<ul style="list-style-type: none"> • Weather disruption • Lower RPE (LUPA) • Payroll tax reset • Short Month (Feb.) • Lower Hospice ADC & Higher Salary Cost per Day 	<ul style="list-style-type: none"> • Highest Completed Episodes • Stronger revenue per episode (RPE) 	<ul style="list-style-type: none"> • Incremental holiday vs. 1H • High PTO • Lower Volumes • Health Insurance Increases • Raises 	<ul style="list-style-type: none"> • Incremental holiday vs. 1H • Health Insurance Increases • Better Volumes • Raises